Finanzen von Aura Biosciences, Inc. (AURA)AURAAura Biosciences, Inc.

Evaluating the bottom line, Aura Biosciences, Inc. maintains a gross margin of N/A. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at N/A, while the net margin is N/A. These profitability ratios, combined with a Return on Equity (ROE) of -53.49%, provide a clear picture of how effectively AURA converts its operational activities into shareholder value.

In the context of the broader market, AURA competes directly with industry leaders such as MNPR and NGNE. With a market capitalization of $797.49M, it holds a leading position in the sector. When comparing efficiency, AURA's gross margin of N/A stands against MNPR's N/A and NGNE's N/A. Such benchmarking helps identify whether Aura Biosciences, Inc. is trading at a premium or discount relative to its financial performance.

Aura has been experiencing significant financial losses, with a net income loss of $45.64 million reported for Q2 2026, a 70% increase year-over-year. The company also has a negative EPS of -0.48 for the last quarter and a forward P/E ratio of 0, indicating no earnings expected in the near term.